title: Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation.
abstract: •Molecular testing may play a role in the determination of targeted therapy treatment options.•Targeted therapy provides treatment options for recurrent cervical cancer.•MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.
authors.affiliation: Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, United States.
authors.forename: Yasmin A
authors.initials: YA
authors.lastname: Lyons
authors.affiliation: Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
authors.forename: Michael
authors.initials: M
authors.lastname: Frumovitz
authors.affiliation: Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
authors.forename: Pamela T
authors.initials: PT
authors.lastname: Soliman
keywords: KRAS mutation; MEK inhibitor; Small cell neuroendocrine carcinoma